Literature DB >> 10915029

Should patients be given an initial low test dose of sildenafil?

J S Cohen1.   

Abstract

Sildenafil is highly effective for treating erectile dysfunction (ED). However, its use has been associated with serious adverse events including myocardial infarctions and strokes, and 130 verifiable plus 112 unverified deaths reported to the US Food and Drug Administration during the 8 months after sildenafil was introduced in the US, and 522 reported deaths during the 13.5 months after its introduction. Moreover, some events have occurred in men taking their first dose of the agent, suggesting that sildenafil, like some drugs that affect blood pressure, may provoke a first-dose reaction. This possibility warrants extra caution to be used when initiating treatment with sildenafil. Such caution is not currently provided by the current dosage guidelines that, for example, recommend the use of sildenafil 50 mg initially for most men between the ages of 18 and 65 years, despite wide differences in bodyweight, age, drug metabolism, health status and usage of other medications. It can be difficult to identify the patient who may be unusually sensitive to the effects of sildenafil. Exercise stress tests have been recommended, but serious adverse events have occurred in men with normal stress tests following the ingestion of sildenafil. Blood pressure monitoring following sildenafil administration will not prevent a serious adverse drug event already in progress. This article discusses the advantages and disadvantages of initiating treatment with a low test dose of sildenafil, performed at home or in the doctor's office. The advantages of this approach include: (i) identifying patients who are highly sensitive to the effects of sildenafil and who may need no higher dose; (ii) minimising adverse effects such as flushing and dizziness that often frighten patients and may affect adherence; (iii) avoidance of major adverse events; and (iv) reassuring patients with ED who remain wary about trying sildenafil therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10915029     DOI: 10.2165/00002018-200023010-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  33 in total

1.  Unexpected first dose hypotensive reaction to enalapril.

Authors:  P J Mullen
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

2.  Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group.

Authors:  H Padma-Nathan; W D Steers; P A Wicker
Journal:  Int J Clin Pract       Date:  1998-09       Impact factor: 2.503

3.  Sildenafil in the treatment of erectile dysfunction.

Authors:  I Schwartz; D McCarthy
Journal:  N Engl J Med       Date:  1998-09-03       Impact factor: 91.245

Review 4.  The role of SSRIs in panic disorder.

Authors:  D V Sheehan; K Harnett-Sheehan
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384

Review 5.  ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association.

Authors:  M D Cheitlin; A M Hutter; R G Brindis; P Ganz; S Kaul; R O Russell; R M Zusman
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

6.  Atrial fibrillation and continuous hypotension induced by sildenafil in an intermittent WPW syndrome patient.

Authors:  K Hayashi; K K Minezaki; M Narukawa; M Ookubo; T Mitsuhashi; K Shimada
Journal:  Jpn Heart J       Date:  1999-11

7.  Sildenafil for iatrogenic serotonergic antidepressant medication-induced sexual dysfunction in 4 patients.

Authors:  H G Nurnberg; J Lauriello; P L Hensley; L M Parker; S J Keith
Journal:  J Clin Psychiatry       Date:  1999-01       Impact factor: 4.384

8.  Sildenafil, a novel effective oral therapy for male erectile dysfunction.

Authors:  M Boolell; S Gepi-Attee; J C Gingell; M J Allen
Journal:  Br J Urol       Date:  1996-08

9.  [Prolonged hypotension after the first dose of atenolol (author's transl)].

Authors:  J Montoliu; A Botey; A Darnell; L Revert
Journal:  Med Clin (Barc)       Date:  1981-04-25       Impact factor: 1.725

10.  Pupil-sparing third nerve palsy associated with sildenafil citrate (Viagra).

Authors:  S P Donahue; R J Taylor
Journal:  Am J Ophthalmol       Date:  1998-09       Impact factor: 5.258

View more
  1 in total

Review 1.  A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.

Authors:  D Vitezic
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.